In compliance with the disclosure obligations set forth in Article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, and as a follow-up to the disclosure of inside information sent to the National Securities Market Commission (Comisión Nacional del Mercado de Valores) and disclosed to the market on 29 September 2025 (with official registration number 2907), Laboratorios Farmaceúticos ROVI, S.A. (hereinafter "ROVI" or the "Company") hereby announces that the Asset Purchase Agreement signed between its subsidiary ROIS Phoenix Inc. (hereinafter “ROIS Phoenix” or the “Buyer”) and Bristol Myers Squibb (“BMS”) for the acquisition of a pharmaceutical manufacturing plant located in Phoenix, Arizona (United States of America) (the “Plant”) together with a series of related assets and liabilities has been executed (the “Operation”).

The consummation of the aforementioned Asset Purchase Agreement has taken place upon the satisfaction of the customary closing conditions for transactions of this nature and in the absence of any material adverse change since its execution.

As previously announced, in connection with the Operation, the Buyer has entered into a toll manufacturing agreement with BMS (the "Toll Manufacturing Agreement"), which governs the terms and conditions under which ROIS Phoenix will continue to manufacture for BMS at the Plant with the personnel required to ensure its operability under said terms and conditions that were previously disclosed.

The Operation represents a strategic acquisition for ROVI and a key milestone towards achieving its vision of becoming one of the leading global manufacturers of high-value-added injectables (pre-filled syringes, cartridges and vials).